Wiergowska, G.; Stasiłowicz, A.; Miklaszewski, A.; Lewandowska, K.; Cielecka-Piontek, J.
Structural Polymorphism of Sorafenib Tosylate as a Key Factor in Its Solubility Differentiation. Pharmaceutics 2021, 13, 384.
https://doi.org/10.3390/pharmaceutics13030384
AMA Style
Wiergowska G, Stasiłowicz A, Miklaszewski A, Lewandowska K, Cielecka-Piontek J.
Structural Polymorphism of Sorafenib Tosylate as a Key Factor in Its Solubility Differentiation. Pharmaceutics. 2021; 13(3):384.
https://doi.org/10.3390/pharmaceutics13030384
Chicago/Turabian Style
Wiergowska, Gabriela, Anna Stasiłowicz, Andrzej Miklaszewski, Kornelia Lewandowska, and Judyta Cielecka-Piontek.
2021. "Structural Polymorphism of Sorafenib Tosylate as a Key Factor in Its Solubility Differentiation" Pharmaceutics 13, no. 3: 384.
https://doi.org/10.3390/pharmaceutics13030384
APA Style
Wiergowska, G., Stasiłowicz, A., Miklaszewski, A., Lewandowska, K., & Cielecka-Piontek, J.
(2021). Structural Polymorphism of Sorafenib Tosylate as a Key Factor in Its Solubility Differentiation. Pharmaceutics, 13(3), 384.
https://doi.org/10.3390/pharmaceutics13030384